Carmot Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• Placebo as SC Injection
  Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.

Phase 2 pipeline

• CT-388
• CT-868
  CT-868 is a selective inhibitor of a molecular target being developed for metabolic or inflammatory disease.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Carmot Therapeutics, Inc. portfolio CI brief
• Carmot Therapeutics, Inc. pipeline updates RSS